DC Initiative 81, which passed with overwhelming support last fall, goes into effect Monday, March 15. Under the Entheogenic Plant and Fungus Policy Act of 2020, natural psychedelics including magic mushrooms, ayahuasca, and mescaline are decriminalized, making arrests for their possession or use the lowest priority for DC police.

WRITTEN BY ANDREW BEAUJON 

The law survived a 30-day Congressional review period and a threat by US Representative Andy Harris, who prevented the District from fully legalizing cannabis following a 2014 ballot initiative that passed with support from 70 percent of DC voters, to derail it. Harris, who set off a metal detector near the House floor while carrying a concealed gun this January, had framed the matter as a public-safety issue.

WASHINGTON, DC – FEBRUARY 5: A DC resident has an operation growing psilocybin mushrooms, including this Galindoi variation of Psilocybe mexicana mushrooms, in Washington, DC, on Monday, February 5, 2020. With the legalization of marijuana, advocates are now pushing for other legalizations, like psilocybin mushrooms. Activists in Colorado, Oregon and California have pushed for approval of psilocybin mushrooms and now folks in the District are starting. Many claim medicinal uses – depression, PTSD and other disorders – as is the case in some European countries. (Photo by Jahi Chikwendiu/The Washington Post)

Initiative 81 was put forward by Melissa Lavasani, who credits natural psychedelics with helping her overcome anxiety, severe depression, panic attacks, and suicidal ideation after the birth of her second child. 

David Bronner, the top executive at Dr. Bronner’s soap company, helped bankroll the campaign, which had to overcome pandemic restrictions to gather signatures and get on the ballot last fall.

Lavasani’s Plant Medicine Coalition on Monday announced it would offer community grants to organizations that offer education, training, and other work that supports the use of natural psychedelics, which have shown intriguing results in the treatment of depression, anxiety, PTSD, and other conditions. Johns Hopkins opened its Center for Psychedelic and Consciousness Research last September.

More on The WASHINGTONIAN

close

LEAVE A REPLY

Please enter your comment!
Please enter your name here